Prior approval opinions and independent opinions of independent directors on the prediction of daily connected transactions in 2022
In accordance with the Listing Rules of Shenzhen Stock Exchange, the governance standards of listed companies, the guiding opinions on the establishment of independent director system in listed companies, the articles of association, the independent director system and other relevant regulations and systems, as independent directors of Berry Genomics Co.Ltd(000710) (hereinafter referred to as the “company”), we hereby express the following opinions on the expected daily related party transactions of the company in 2022:
1、 Prior approval opinion
1. The daily related party transactions of the company in 2022 are the continuation of the previous business, which is based on the distribution agreement signed with Fujian Herui Gene Technology Co., Ltd. (hereinafter referred to as “Fujian Herui”) (see the company’s website on November 17, 2017 for details)（ http://www.cn.info.com.cn. ）The disclosed announcement on giving up the preemptive right to increase capital and shares of subsidiaries and related party transactions (Announcement No.: 2017080)) and the prediction of future business development needs meet the needs of the company’s daily operation.
2. The above-mentioned daily related party transactions in 2022 are not expected to have an impact on the independence of the company, the company’s main business will not rely on related parties due to related party transactions, and there is no behavior damaging the interests of the company and shareholders, especially minority shareholders.
3. We agree to submit the above proposal to the 16th meeting of the 9th board of directors of the company for deliberation, and directors associated with this proposal need to avoid voting.
2、 Independent opinion
We have carefully considered the proposal on the prediction of daily related party transactions in 2022 and believe that the company expects the daily related party transactions in 2022 to be normal business planning. As a continuation of the daily related party transactions in 2021, this daily related party transaction is a normal business transaction, meets the needs of the company’s daily operation, and is conducted on the basis of fairness, justice and mutual benefit, There is no harm to the interests of the company and minority shareholders, nor will it affect the independence of the company.
When the board of directors of the company considered the above proposal, the affiliated directors Mr. Zhou Daixing, Mr. Wang Junfeng and Ms. Wang Hongxia avoided voting, and the voting procedures were in line with the relevant provisions of the stock listing rules of Shenzhen Stock Exchange, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 7 – transactions and affiliated transactions, and the articles of association, We agree with the company’s proposal on the prediction of daily connected transactions in 2022.
Independent directors: Wang Xiuping, Li Guangchao, Wang Sijia April 14, 2022
